How Medtech Founders Should Build a Product Launch Strategy Before FDA Clearance

A medtech product launch strategy has to start before FDA clearance, not after it. Category definition, messaging, and narrative have to exist before the initial product release, because clearance alone does not tell a buyer why the device matters.

Key Takeaways

• A medtech product launch strategy that starts at FDA clearance is already a year behind, because category definition has to happen before the initial product release, not after.
• Bruce Cleveland's diagnosis: FDA clearance is table stakes now, not an outcome. Founders still have to build an educated market on top of it.
• Gene Nagel hires marketing leadership a full year before launch, because learning the product, the market, and the customer base cannot be compressed into the weeks before clearance.
• The clearest diagnostic for a missing launch strategy: if every sales conversation requires re-educating the buyer from scratch, that's a market problem, not a sales problem.
• Founders who sequence category definition before FDA clearance avoid scaling confusion into a market that was never prepared to receive the product.

Watch the full episode on YouTube

Why a Product Launch Strategy Has to Start With Category Definition

Most medtech founders sequence launch work in the order that feels natural: build the product, clear FDA, hire sales, run marketing. That order treats category definition as optional, and it's the single biggest reason a launch underperforms.

I covered this on an episode about how market engineering helps medtech startups raise capital:

"You got to think about a minimal viable category, meaning you got to name and define a category or consider redefining one. After that, you get to your initial product release, your first publicly deployed product iteration. Then you get to minimally viable product, usually after you get through FDA."

That sequence puts category definition first, before the product even ships publicly. Founders who skip it and go straight to clearance are building a launch strategy with no foundation underneath the product.

The category has to exist in the buyer's head before the device does. Skip that step, and the product launches into a vacuum no amount of post-clearance marketing can fill quickly.

Why FDA Clearance Alone No Longer Guarantees a Buyer

A medtech product launch strategy built entirely around clearing FDA assumes the market still works the way it did fifteen years ago. It doesn't, and founders who plan around the old assumption get blindsided.

I interviewed Bruce Cleveland on an episode about product-market fit, category design, and why startups waste funding. He named the shift directly:

"Nowadays, you have to build a great company. Building a great company means you have to build an educated market. You have to do thought leadership. It's not enough just to have a cool product with some IP and then you get FDA clearance."

Cleveland's point is structural. A generation ago, a good product with FDA clearance was often enough to get acquired. That path has closed for most companies now.

A product launch strategy built only around the clearance milestone is optimizing for a market condition that no longer exists. The company still has to educate the buyer, and that work has to be planned before clearance, not scrambled together after it.

Why Hiring Marketing a Year Before Launch Beats Hiring at Clearance

Founders often wait until FDA clearance is close before hiring the person responsible for launch. By then, there's no time left to learn the product, the market, and the customer before the clock starts.

Gene Nagel, who runs medical device sales training programs, described his own standard on an episode about fixing medical sales training:

"If you have a product launch coming up, you need to hire that head of marketing minimum a year out, because they need to get situated in the role. They need to learn the product inside out, they need to learn the market, they need to talk to customers."

A year sounds long until it's mapped against everything a launch leader has to absorb: the clinical mechanism, the buying committee, the objections a surgeon raises in the first five minutes of a pitch.

Founders who hire at clearance are asking someone to learn all of that while simultaneously executing a launch. Founders who hire a year out get a launch strategy built by someone who understands what they're launching.

What Diagnostic Question Reveals a Missing Market, Not a Sales Problem

Founders who launch without a strategy in place usually misdiagnose the failure. Sales underperforms, so the instinct is to blame sales execution. That diagnosis is almost always wrong.

I covered the actual diagnostic on the same episode about market engineering and medtech capital:

"If every one of your deals, even in the early days when you're the founder reaching out to a customer, requires you educating or re-educating, reframing, explaining basic things about the problem and the solution, that's literally missing the market."

That test is simple to run. If every conversation starts from zero, the category doesn't exist yet in the buyer's head, no matter how skilled the person running the conversation is.

A medtech product launch strategy built correctly removes that re-education burden before the first sales call happens. The buyer already recognizes the category. The rep's job becomes closing, not teaching from scratch every single time.

What This Means for Medtech Founders

In my experience working with medtech founders, the ones who get launch sequencing wrong aren't skipping steps out of carelessness. They're following the order that looks efficient: build, clear, hire, launch.

That order assumes the market already understands the category the product competes in. For most genuinely new medtech, it doesn't, and a launch strategy built on that false assumption discovers the gap the hard way, mid-launch, with a sales team that can't close.

The founders who get this right start category work before clearance, hire launch leadership a year out instead of at the finish line, and run the re-education test on every early sales conversation to catch a missing market before it costs a launch quarter.

A product launch strategy is not something that starts once FDA says yes. It has to be built while the product is still being built, so the market is ready the moment the device is.

Frequently Asked Questions

When Should a Medtech Product Launch Strategy Begin?

Category definition and market education should begin well before FDA clearance, ideally alongside product development. Founders who wait until clearance to start planning the launch are compressing work that needs months, not weeks, into a narrow pre-launch window.

Why Doesn't FDA Clearance Guarantee Commercial Success Anymore?

Clearance proves the product works. It doesn't prove the market understands why the product matters or when to use it. Buyers, investors, and strategics increasingly expect a defined category and clear narrative before they engage, not just a cleared device.

How Do Founders Know if They Have a Launch Strategy Problem Versus a Sales Problem?

Run the re-education test. If sales conversations consistently require explaining the problem and the solution from scratch, the category hasn't been defined clearly enough yet. That's a market gap, not a training or hiring issue on the sales side.

Where to Go From Here

If you're doing this yourself. Read the medtech commercialization strategy breakdown to see how category definition sequences against clearance, hiring, and go-to-market.

If you want it engineered with you. MarketCraft takes on a small number of medtech teams each quarter, starting with The Market Engineering Audit. For founders planning a launch, the audit checks whether the category is defined before the clock on clearance starts running.

Listen to the Full Conversations

• How Market Engineering Helps MedTech Startups Raise Capital
• Bruce Cleveland: The Truth About Product-Market Fit, Category Design and Why Startups Waste Funding
• The Problem with Medical Sales Training and How to Fix It With Gene Nagel

Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.